Immunosuppressants
- PDF / 143,482 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 85 Downloads / 192 Views
1
S
Burkitt post-transplant lymphoproliferative disorder: 8 case reports Seven men and one woman, aged 18–54 years, developed Burkitt’s post-transplant lymphoproliferative disorder (PTLD) while receiving immunosuppression including ciclosporin, tacrolimus, mycophenolate mofetil, azathioprine, and/or prednisolone [routes and durations of treatment to reaction onset not stated]. Between 1995 and 2009 the patients had developed PTLD, 85–4555 days after transplantation. At the time of diagnosis, five were receiving ciclosporin 150–300 mg/day, and three were receiving tacrolimus 1.5–8 mg/day. Three patients were receiving an antimetabolite, which was mycophenolate mofetil in two (720 and 1000 mg/day), and azathioprine 150 mg/day in one. Three were receiving prednisolone, in dosages ranging from 5–15 mg/day. The immunosuppressive regimen was not changed in three patients. Ciclosporin was stopped in two patients, with a concomitant increase in prednisolone in one and a decrease in mycophenolate mofetil dosage in the other; ciclosporin was reduced in a third patient. Azathioprine was stopped in another, and tacrolimus was down-titrated in the last. They all underwent chemotherapy, and complete response was achieved in six patients. At last follow-up, four patients were dead (cause described as being disease related/treatment related in one), and four were in complete remission. Author comment: Post-transplantation lymphoproliferative disorder "is a spectrum of lymphoproliferations associated with the use of potent immunosuppressive drugs after transplantation". Zimmermann H, et al. Burkitt post-Transplantation lymphoma in adult solid organ transplant recipients: Sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or RCHOP is safe and effective in an analysis of 8 patients. Cancer 118: 4715-4724, No. 19, Oct 2012. Available from: URL: http://dx.doi.org/10.1002/cncr.27482 803080502 Germany
0114-9954/10/1431-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 8 Dec 2012 No. 1431
Data Loading...
